17:57 uur 09-09-2021

Valbiotis publiceert brief aan aandeelhouders voor 2021

LA ROCHELLE, Frankrijk–(BUSINESS WIRE)– Nieuws over regelgeving:

Valbiotis (FR0013254851 – ALVAL, in aanmerking komend voor PEA/SME) (Parijs:ALVAL), een onderzoeks- en ontwikkelingsbedrijf dat zich inzet voor wetenschappelijke innovatie voor het voorkomen en bestrijden van metabole ziekten, kondigt de publicatie aan van de laatste uitgave van haar Brief aan de aandeelhouders, voor 2021.

In deze brief aan aandeelhouders:

  • Een bericht van Sébastien PELTIER, CEO, voorzitter van de raad van bestuur van Valbiotis;
  • Een samenvatting van het laatste nieuws van het bedrijf;
  • Een update over de voortgang van het ontwikkelingsplan voor werkzame stoffen.

De brief aan de aandeelhouders kan worden geraadpleegd in het gedeelte ‘Investeerders’ van de Valbiotis-website, in het gedeelte ‘Aandeelhoudersgedeelte‘.

Om de volgende edities te ontvangen, worden aandeelhouders uitgenodigd om zich hier te registreren.

Over Valbiotis

Valbiotis is een onderzoeks- en ontwikkelingsbedrijf dat zich inzet voor wetenschappelijke innovatie voor de behandeling en preventie van metabole ziekten als reactie op onvervulde medische behoeften.

Valbiotis Releases its Letter to Shareholders for 2021

LA ROCHELLE, France–(BUSINESS WIRE)– Regulatory News:

Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the release of the latest issue of its Letter to Shareholders, for 2021.

In this Letter to Shareholders:

  • A message from Sébastien PELTIER, CEO, Chairman of the Valbiotis Management Board;
  • A summary of the Company’s latest news;
  • An update on the progress of the active substances development plan.

The Letter to shareholders can be consulted in the “Investors” area of the Valbiotis website, in the “Shareholder area” section.

To receive the next editions, shareholders are invited to register here.

About Valbiotis

Valbiotis is a Research & Development company committed to scientific innovation for the treatment and prevention of metabolic diseases in response to unmet medical needs.

Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.

Its products are intended to be licensed to players in the health sector.

Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).

Valbiotis is a member of the “BPI Excellence” network and has been recognized as an “Innovative Company” by the BPI label. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information about Valbiotis, please visit: www.valbiotis.com

Name: Valbiotis

ISIN code: FR0013254851

Mnemonic code: ALVAL

EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document approved by the French Financial Markets Regulator (AMF) on July 27, 2021 (application number R 21-039). This document is available on the Company’s website (www.valbiotis.com).

This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.


Corporate communication / Valbiotis


+33 5 46 28 62 58


Financial communication / Actifin

Stéphane RUIZ

+33 1 56 88 11 14


Check out our twitter: @NewsNovumpr